Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Moodys
Medtronic
Harvard Business School
Baxter

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,324,283

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,324,283 protect, and when does it expire?

Patent 8,324,283 protects GILENYA and is included in one NDA.

Protection for GILENYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety-nine patent family members in forty-two countries.

Summary for Patent: 8,324,283
Title:Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol
Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor agonist; and (b) a sugar alcohol.
Inventor(s): Oomura; Tomoyuki (Oita, JP), Pudipeddi; Madhusudhan (Edison, NJ), Ruegger; Colleen (Morris Plains, NJ), Royce; Alan E (Saylorsburg, PA), Sasaki; Masaki (Oita, JP), Tamura; Tokuhiro (Fukuoka, JP)
Assignee: Novartis AG (Basel, CH) Mitsubishi Pharma Corporation (Osaka, JP)
Application Number:12/189,323
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,324,283
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Use;

Drugs Protected by US Patent 8,324,283

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Harvard Business School
McKesson
Medtronic
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.